middle.news
How Tetratherix’s Deal with Henry Schein Could Transform Bone Regeneration Markets
8:40am on Monday 19th of January, 2026 AEDT
•
Healthcare
Read Story
How Tetratherix’s Deal with Henry Schein Could Transform Bone Regeneration Markets
8:40am on Monday 19th of January, 2026 AEDT
Key Points
Global exclusive distribution agreement signed with Henry Schein
First product, Tegenix, targets bone regeneration in dental surgery
Commercial launch anticipated in FY27 post FDA 510(k) clearance
Construction underway for expanded manufacturing facility in NSW
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
TETRATHERIX (ASX:TTX)
OPEN ARTICLE